Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.76 |
| ▸ | HRH4 | Q9H3N8 | 9/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | HRH2 | P25021 | 2/20 | 0.55 |
| ▸ | HRH1 | P35367 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MIF | P14174 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | APEX1 | P27695 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31157562 | 0.85 | HRH3 (1.00) | HRH3HRH4HRH2HRH1 | |
| SCHEMBL17383815 | 0.82 | HRH3 (0.60) | HRH3HRH4MEN1ALDH1A1MAPT | |
| SCHEMBL8963903 | 0.79 | HRH3 (0.73) | HRH3HRH4MEN1ALDH1A1MAPT | |
| SCHEMBL18947719 | 0.78 | — | — | |
| SCHEMBL13464166 | 0.76 | QPCT (0.53) | HRH3HRH4MEN1ALDH1A1MAPT | |
| SCHEMBL8963886 | 0.75 | HRH3 (0.75) | HRH3HRH4HRH2HRH1LMNA | |
| SCHEMBL8964986 | 0.75 | HRH3 (0.79) | HRH3HRH4HRH2HRH1 | |
| SCHEMBL18880433 | 0.75 | TAAR1 (0.61) | HRH3HRH4 | |
| Hydrochloric Acid SCHEMBL1696889 | 0.73 | HRH3 (0.96) | HRH3HRH4MEN1ALDH1A1MAPT | |
| SCHEMBL28277441 | 0.73 | HRH3 (0.49) | HRH3HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879808-B2 | potent activity against resistant pneumococci; for treating domestic fowl | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2010-08-19 | — | — | US | disclosed |
| EP-2151447-A1 | LINCOMYCIN DERIVATIVES AND ANTIBACTERIAL AGENTS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | Meiji Seika Kaisha Ltd. (JP) | 2010-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | LAS1L, LCLAT1, LYPLA1 | HRH3 2518/4885HRH4 2138/4885MEN1 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.